Profile picture

Professor David Adams

Le Kremlin-Bicetre Cedex (France)
Follow
Logo ESC

Contributor content

Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement
Presentation
Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement
Read more

ESC 365 is supported by

novartis Explore sponsored resources